Efficacy and Safety of Paricalcitol Therapy for Kidney Transplantation Recipients: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Authors

Bo Wang, Yao Liu, Bangcai Wu, Chuan Hu, Junjie Yu, Lei Cao

Published in

Transplantation proceedings. Sep 16, 2026. Epub Sep 16, 2026.

Abstract

To evaluate the efficacy and safety of paricalcitol in kidney transplant recipients while accounting for the small and clinically heterogeneous randomized evidence base.
The original multi-database search was supplemented by targeted PubMed and ClinicalTrials.gov surveillance through July 6, 2026. Eligible randomized trials comparing paricalcitol with inactive control were synthesized using random-effects models with small-sample-adjusted confidence intervals.
Six randomized trials involving 482 recipients were included. Paricalcitol reduced parathyroid hormone (SMD, -0.74; 95% CI, -1.23 to -0.24; p = .01; I² = 52%) but did not show a clear reduction in proteinuria (SMD, -0.22; 95% CI, -0.50 to 0.06; p = .10; I² = 0%). Serum calcium increased (SMD, 0.36; 95% CI, 0.03 to 0.68; p = .04; I² = 25%), and hypercalcemia was more frequent (RR, 3.71; 95% CI, 1.21 to 11.36; p = .03; I² = 0%). Serum phosphorus (SMD, 0.11; 95% CI, -0.18 to 0.40; p = .34; I² = 0%) and rejection events (RR, 0.78; 95% CI, 0.10 to 6.45; p = .67; I² = 0%) remained inconclusive.
Paricalcitol lowers short-term parathyroid hormone but increases serum calcium and hypercalcemia risk. Evidence for proteinuria, rejection, graft survival, and patient outcomes remains insufficient because the trials were few, heterogeneous, and short.

PMID:
42749567
Bibliographic data and abstract were imported from PubMed on 17 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.